The partnership aims to expedite the creation of precise treatments to improve results for solid tumour patients.

Bispecific Antibodies Market size Expected to surpass USD 40 Biilion By 2029 Says Kuick ResearchDelhi, Oct. 04, 2024 (GLOBE ...

Wuhan YZY Biopharma Co. Ltd. is out-licensing lead candidate M-701, a CD3/EpCAM bispecific antibody, to Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (CTTQ) for China rights in a deal worth up to ...

During a Case-Based Roundtable® event, Christopher Maisel, MD, discussed third- and fourth-line therapy and barriers to ...

Triveni Bio has roped in $115 million in series B funds to advance preclinical antibody programs designed to treat ...

BioAtla, Inc. faces financial challenges but presents promising pipeline projects in cancer treatment, offering opportunities ...

BioAtla faces a tight cash runway until Q3 2025, raising concerns about dilution and short-term stock headwinds. Find out why ...

Ajai Chari, MD, covered both recent FDA approvals and pipeline products, such as non-BCMA chimeric antigen receptor (CAR) ...

Treatment with AGA2118, a bispecific antibody targeting both sclerostin and DKK1, led to rapid and durable increases in bone formation, decreases in bone resorption, and improvements in bone mineral ...

A copy of the presentation materials can be accessed on the “Publication” section of the Company’s website at www.bioatla.com once the presentation has concluded. About BioAtla®, Inc.

The global antibody market is set to reach USD 581.42 billion by 2034 , growing at a CAGR of 8.1% from 2024. The therapeutic ...